Skip to main content

Table 1 Characteristics of patients enrolled in study

From: Evaluation of 18F-fluorothymidine positron emission tomography ([18F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer

Pt No

Age (years)

Sitea

Stageb

Chemotherapyc

Overall RECIST responsed

SUV60, ave (preRx)

SUV60, max (preRx)

Percentage Change SUV60, ave

Percentage Change SUV60, max

Baseline FDG SUV60, ave

Baseline FDG SUV60,max

Ki-67 (%)

1

63

GEJ

T4N1M1

EOX

PR

5.92

9.45

−35.16

−54.49

43

2

54

Distal

T3N0

ECX, surgery

4.6

4.52

−25.65

−5.75

5.93

4.38

3

68

Distal

T3N0M1

EOX

SD

5.32

7.47

−2.26

4.95

6.76

5.63

87

4

76

GEJ

T3N1M1

ECX

PR

4.97

7.25

6.44

5.66

21.45

19.96

29

5

71

GEJ

T3N0M0

EOX

SD

6.08

9.96

11.51

11.14

14.91

14.06

23

6

64

GEJ

T4N1M1

EOX

SD

5.5

8.85

−30.73

−47.57

10.44

9.03

7

65

Gastric

T3N1M0

EOX, Surgery

PR

4.14

7.62

−15.22

−16.93

7e

     

3.65

8.87

1.92

29.76

   

8

60

Distal

T3N1M0

ECX, surgery

SD

7.7

13.36

−29.61

−33.08

9

54

Gastric

T3N1M0

EOX/STO3

SD

3.66

5.93

−24.86

−25.46

51

10

69

Distal

T3N0M0

ECX, surgery

SD

4.79

9.3

−18.99

−24.09

13.88

12.24

67.5

  1. a GEJ gastro-oesophageal junction, distal distal oesophagus
  2. bStage according to TNM criteria, CT and EUS used
  3. c EOX epirubicin, oxaliplatin and capecitabine, ECX epirubicin, cisplatin and capecitabine, ST03 study - ECX +/- bevacizumab
  4. dRECIST criteria: PR partial response, SD stable disease, PD progressive disease
  5. eLymph node >20 mm, included as a target lesion in final analysis